Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-7714 (Electronic) Linking ISSN: 15423565 NLM ISO Abbreviation: Clin Gastroenterol Hepatol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : W.B. Saunders for the American Gastroenterological Association, 2003-
    • Subject Terms:
      Adenocarcinoma*/complications ; Adenocarcinoma*/epidemiology ; Barrett Esophagus*/complications ; Barrett Esophagus*/epidemiology ; Esophageal Neoplasms*/complications ; Esophageal Neoplasms*/epidemiology ; Gastroesophageal Reflux*/epidemiology ; Gastroesophageal Reflux*/etiology; Humans ; Prevalence
    • Abstract:
      Background and Aims: Although gastroesophageal reflux disease (GERD) symptoms are an essential criterion for Barrett's esophagus (BE) screening in most gastroenterology society guidelines, a significant proportion of BE and esophageal adenocarcinoma (EAC) cases do not endorse them. In a systematic review and meta-analysis, we aimed to study the prevalence of BE/EAC in those with and without GERD.
      Methods: A systematic search was conducted through 5 major databases for studies reporting prevalence of BE/EAC in patients with and without GERD. Pooled proportions and odds ratios (ORs) of BE, long-segment BE, short-segment BE, dysplasia, and EAC in patients with and without GERD were synthesized.
      Results: Forty-three articles (12,883 patients with GERD; 51,350 patients without GERD) were included in the final analysis. BE prevalence was 7% (95% confidence interval [CI], 5.8%-8.5%) and 2.2% (95% CI, 1.6%-3%) among individuals with and without GERD, respectively. EAC prevalence was 0.6% (95% CI, 0.4%-1%) and 0.1% (95% CI, 0%-0.2%) in those with and without GERD, respectively. The overall risks for BE (OR, 2.91; 95% CI, 2.06-4.11) and long-segment BE (OR,4.17; 95% CI, 1.78-9.77) were higher in patients with GERD, but the risk for short-segment BE (OR, 1.77; 95% CI, 0.89-3.52) did not differ between the two groups. In 9 population-based high-quality studies (2244 patients with GERD; 3724 patients without GERD), BE prevalence in patients without GERD was 4.9% (95% CI, 2.6%-9%). BE prevalence was highest in North American studies (10.6% [GERD] and 4.8% [non-GERD]).
      Conclusions: BE prevalence in those without GERD is substantial, particularly in large high-quality population-based studies. These data are important to factor in future BE/EAC early detection guidelines.
      (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
    • References:
      Medicine (Baltimore). 2016 Apr;95(14):e3313. (PMID: 27057907)
      Scand J Gastroenterol. 1999 Nov;34(11):1065-70. (PMID: 10582754)
      Am J Gastroenterol. 2021 Aug 1;116(8):1620-1631. (PMID: 34131096)
      PLoS One. 2014 Mar 18;9(3):e92001. (PMID: 24642729)
      Gastroenterology. 2003 Dec;125(6):1670-7. (PMID: 14724819)
      Dis Esophagus. 2003;16(1):29-32. (PMID: 12581251)
      Lancet. 1994 Dec 3;344(8936):1533-6. (PMID: 7983953)
      Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
      J Clin Gastroenterol. 2013 Oct;47(9):762-8. (PMID: 23751847)
      Int J Cancer. 1991 May 30;48(3):364-8. (PMID: 2040529)
      Dis Esophagus. 2009;22(8):649-55. (PMID: 19515192)
      JAMA. 1995 Aug 9;274(6):474-7. (PMID: 7629956)
      Dig Dis Sci. 2004 Feb;49(2):237-42. (PMID: 15104363)
      Am J Gastroenterol. 2009 Sep;104(9):2145-52. (PMID: 19513020)
      BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
      Dig Dis Sci. 2010 May;55(5):1337-43. (PMID: 19557516)
      Gastroenterology. 2009 Sep;137(3):815-23. (PMID: 19524578)
      Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. (PMID: 31439127)
      Am J Gastroenterol. 2015 Jan;110(1):148-58. (PMID: 25488897)
      Therap Adv Gastroenterol. 2019 Jun 03;12:1756284819853115. (PMID: 31210784)
      Dis Esophagus. 2000;13(1):5-11. (PMID: 11005324)
      Clin Gastroenterol Hepatol. 2022 Dec;20(12):2696-2706.e1. (PMID: 35788412)
      Dig Dis Sci. 2009 Mar;54(3):572-7. (PMID: 18654849)
      Am J Gastroenterol. 2010 Aug;105(8):1729, 1730-7; quiz 1738. (PMID: 20485283)
      Medicine (Baltimore). 2020 Aug 21;99(34):e21791. (PMID: 32846811)
      Gastrointest Endosc. 2021 Feb;93(2):409-419.e1. (PMID: 32565183)
      Laryngoscope. 2012 Aug;122(8):1719-23. (PMID: 22565357)
      Am J Gastroenterol. 2020 Aug;115(8):1201-1209. (PMID: 32558685)
      J Med Libr Assoc. 2016 Jul;104(3):240-3. (PMID: 27366130)
      Aliment Pharmacol Ther. 2006 Mar 1;23(5):595-9. (PMID: 16480398)
      Am J Gastroenterol. 2013 Mar;108(3):353-62. (PMID: 23318485)
      Rev Gastroenterol Mex. 2017 Oct - Dec;82(4):296-300. (PMID: 28687434)
      Gut. 2008 Oct;57(10):1354-9. (PMID: 18424568)
      Gastroenterology. 2002 Aug;123(2):461-7. (PMID: 12145799)
      Am J Gastroenterol. 2022 Apr 1;117(4):559-587. (PMID: 35354777)
      Dig Dis Sci. 1997 Mar;42(3):603-7. (PMID: 9073146)
      Dig Dis Sci. 2016 Nov;61(11):3221-3228. (PMID: 27510751)
      Lancet. 2020 Aug 1;396(10247):333-344. (PMID: 32738955)
      N Engl J Med. 1999 Mar 18;340(11):825-31. (PMID: 10080844)
      Gastroenterology. 2006 Nov;131(5):1392-9. (PMID: 17101315)
      J Dig Dis. 2010 Apr;11(2):83-7. (PMID: 20402833)
      JAMA. 2000 Apr 19;283(15):2008-12. (PMID: 10789670)
      J Gastroenterol Hepatol. 2022 Aug;37(8):1507-1516. (PMID: 35614860)
      Gut. 2014 Jan;63(1):7-42. (PMID: 24165758)
      Fam Cancer. 2023 Jan;22(1):55-60. (PMID: 35653070)
      Clin Endosc. 2014 Jan;47(1):15-22. (PMID: 24570879)
      Dig Liver Dis. 2001 May;33(4):322-5. (PMID: 11432509)
      Int Surg. 2015 Apr;100(4):720-5. (PMID: 25588717)
      Gastroenterology. 2023 Jul;165(1):283-285.e2. (PMID: 37001765)
      Hippokratia. 2013 Jan;17(1):27-33. (PMID: 23935340)
      Iran J Med Sci. 2013 Sep;38(3):263-6. (PMID: 24174698)
      Gastroenterology. 2018 Jan;154(2):390-405. (PMID: 28780073)
      Gastroenterology. 2005 Dec;129(6):1825-31. (PMID: 16344051)
      Gastrointest Endosc. 2009 Nov;70(5):867-73. (PMID: 19640517)
      Am J Gastroenterol. 2006 Jan;101(1):12-7. (PMID: 16405528)
      Clin Gastroenterol Hepatol. 2022 Aug;20(8):1709-1718. (PMID: 34757196)
      Gastrointest Endosc. 2021 Sep;94(3):498-505. (PMID: 33857451)
      Dig Dis Sci. 2010 Jul;55(7):1932-9. (PMID: 19798574)
      J Exp Clin Cancer Res. 2006 Sep;25(3):297-302. (PMID: 17167967)
      Endoscopy. 2009 Dec;41(12):1011-7. (PMID: 19967617)
      Arch Intern Med. 2004 Jul 26;164(14):1482-8. (PMID: 15277277)
      BMC Gastroenterol. 2013 Sep 26;13:143. (PMID: 24070185)
      World J Gastroenterol. 2019 Jul 7;25(25):3231-3241. (PMID: 31333314)
      Dig Dis Sci. 2021 Jul;66(7):2311-2316. (PMID: 32749640)
      J Gastrointestin Liver Dis. 2014 Mar;23(1):19-25. (PMID: 24689092)
    • Grant Information:
      R01 CA241164 United States CA NCI NIH HHS
    • Contributed Indexing:
      Keywords: Epidemiology; Esophageal Cancer; Esophageal Neoplasm; Gastroesophageal Reflux Complications
    • Subject Terms:
      Adenocarcinoma Of Esophagus
    • Publication Date:
      Date Created: 20231025 Date Completed: 20240621 Latest Revision: 20241230
    • Publication Date:
      20241230
    • Accession Number:
      PMC11039569
    • Accession Number:
      10.1016/j.cgh.2023.10.006
    • Accession Number:
      37879525